-+ 0.00%
-+ 0.00%
-+ 0.00%

Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est

Benzinga·05/05/2026 20:08:27
Listen to the news
Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2026 sales outlook from $840.000 million-$870.000 million to $840.000 million-$870.000 million vs $862.242 million estimate.